Faltas, Bishoy Morris

Publications

Sort by

Co-Author Network

selected publications

Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nature reviews. Urology. 2023 Article GET IT
A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer. European urology. 2023 Letter GET IT
Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer. JAMA network open. 2023 Academic Article GET IT
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nature reviews. Urology. 2023 Review GET IT
The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer. Cancer research. 2023 Academic Article GET IT
Times cited: 3
Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfβ-Dependent Mechanisms. Molecular cancer therapeutics. 2022 Academic Article GET IT
Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer. Scientific reports. 2022 Academic Article GET IT
Loss of function mutations in CDKN1A are permissive for APOBEC3-induced mutagenesis in urothelial carcinoma. American journal of cancer research. 2022 Editorial Article GET IT
Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab. 2022 GET IT
Times cited: 3
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Molecular oncology. 2022 Academic Article GET IT
Times cited: 4
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. British journal of cancer. 2022 Academic Article GET IT
Times cited: 6
Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors. NPJ genomic medicine. 2021 Academic Article GET IT
Times cited: 52892
Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. The oncologist. 2021 Academic Article GET IT
Times cited: 6
Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment. American journal of clinical oncology. 2021 Academic Article GET IT
Times cited: 13
Common germline-somatic variant interactions in advanced urothelial cancer. Nature communications. 2020 Academic Article GET IT
Times cited: 13
Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. Translational oncology. 2020 Academic Article GET IT
Times cited: 11
Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. European urology. 2020 Academic Article GET IT
Times cited: 43
Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers. Nature communications. 2020 Academic Article GET IT
Times cited: 29
Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nature reviews. Urology. 2020 Review GET IT
Times cited: 76
A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nature communications. 2020 Academic Article GET IT
Times cited: 85
Pan-cancer analysis of whole genomes. Nature. 2020 Academic Article GET IT
Times cited: 1201
The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing. Cancer treatment and research communications. 2020 Academic Article GET IT
Times cited: 5
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 36
Clinical features of neuroendocrine prostate cancer. European journal of cancer (Oxford, England : 1990). 2019 Academic Article GET IT
Times cited: 138
Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 10
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 105
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature communications. 2019 Academic Article GET IT
Times cited: 102
Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European urology oncology. 2019 Academic Article GET IT
Times cited: 28
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. 2019 GET IT
Times cited: 4
Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma. Expert opinion on therapeutic targets. 2018 Editorial Article GET IT
Times cited: 1
The molecular limitations of biomarker research in bladder cancer. World journal of urology. 2018 Review GET IT
Times cited: 29
Treatment resistance in urothelial carcinoma: an evolutionary perspective. Nature reviews. Clinical oncology. 2018 Review GET IT
Times cited: 30
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018 Academic Article GET IT
Times cited: 65
Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urologic oncology. 2017 Academic Article GET IT
Times cited: 12
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 584
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer discovery. 2017 Academic Article GET IT
Times cited: 589
Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer. Lancet (London, England). 2016 Comment GET IT
Times cited: 1
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature genetics. 2016 Academic Article GET IT
Times cited: 201
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. Urologic oncology. 2016 Academic Article GET IT
Times cited: 24
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urologic oncology. 2016 Review GET IT
Times cited: 38
Application of next-generation sequencing in gastrointestinal and liver tumors. Cancer letters. 2016 Review GET IT
Times cited: 5
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 70
Radical Cystectomy for Bladder Cancer in Patients With and Without a History of Pelvic Irradiation: Survival Outcomes and Diversion-related Complications. Urology. 2015 Academic Article GET IT
Times cited: 12
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA oncology. 2015 Academic Article GET IT
Times cited: 216
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 797
Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer. European urology. 2015 Academic Article GET IT
Times cited: 150
Novel molecular targets for urothelial carcinoma. Expert opinion on therapeutic targets. 2015 Review GET IT
Times cited: 8
Immunologics and chemotherapeutics for renal cell carcinoma. Seminars in interventional radiology. 2014 Review GET IT
Times cited: 9
Myelodysplastic syndromes: toward a risk-adapted treatment approach. Expert review of hematology. 2013 Review GET IT
Times cited: 21
Sequential occurrence of a splenic marginal zone lymphoma, extranodal MALT lymphoma, and Hodgkin lymphoma. 2013 GET IT
Times cited: 2
Myelodysplastic syndromes: what do hospitalists need to know?. Journal of hospital medicine. 2013 Review GET IT
Times cited: 20
Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma. Leukemia & lymphoma. 2012 Letter GET IT
Times cited: 2
Adult primary pulmonary primitive neuroectodermal tumor: molecular features and translational opportunities. 2012 GET IT
Times cited: 22
Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. Frontiers in oncology. 2012 Academic Article GET IT
Times cited: 53
Dabigatran etexilate: what do hospitalists need to know?. Journal of hospital medicine. 2011 Review GET IT
Times cited: 5
Circulating tumor cells in the cerebrospinal fluid: "tapping" into diagnostic and predictive potential. Oncotarget. 2011 Editorial Article GET IT
Times cited: 5
Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Letter GET IT
Times cited: 17
Cancer is an ancient disease: the case for better palaeoepidemiological and molecular studies. Nature reviews. Cancer. 2011 Letter GET IT
Times cited: 10
Mental nerve neuropathy: frequently overlooked clinical sign of hematologic malignancies. The American journal of medicine. 2011 Letter GET IT
Times cited: 7
A new anticoagulant for a new era: review of recent data on dabigatran etexilate. Clinical advances in hematology & oncology : H&O. 2010 Review GET IT
Times cited: 2
Prolonged and increased postoperative risk of venous thromboembolism: rationale for even more 'extended' prophylaxis?. Expert review of hematology. 2010 Comment GET IT
Times cited: 1
Targeting hematogenous spread of circulating tumor cells by a chemotactic drug-eluting IVC filter to prevent pulmonary and systemic metastasis. Medical hypotheses. 2009 Academic Article GET IT
Times cited: 6
Update on perioperative bridging in patients on chronic oral anticoagulation. Expert review of cardiovascular therapy. 2009 Review GET IT
Times cited: 6
Gastric Burkitt lymphoma associated with Efalizumab and Helicobacter pylori. Leukemia & lymphoma. 2009 Letter GET IT
Times cited: 1
A case of primary meningococcal pericarditis caused by Neisseria meningitidis serotype Y with rapid evolution into cardiac tamponade. 2008 GET IT
Times cited: 6
Can't catch a breath. 2007 GET IT
Robotic surgery: applications, limitations, and impact on surgical education. MedGenMed : Medscape general medicine. 2005 Review GET IT
Times cited: 51

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancer awarded by Starr Cancer Consortium Principal Investigator 2023 - 2024
Addgene 699808 awarded by Addgene, Inc. Principal Investigator 2022 - 2023
Immunogenomic determinants of ethnic disparities in clinical outcomes for urothelial cancer patients awarded by National Human Genome Research Institute Principal Investigator 2020 - 2023

An urinary drug disposing approach for treatment of bladder Cancer awarded by National Cancer Institute Co-Investigator 2023 - 2028
Clinical and Translational Science Center - UL1 awarded by National Center for Advancing Translational Sciences Co-Investigator 2022 - 2027

Synthetic lethal strategies to limit tumor evolution driven by APOBEC3 activity in urothelial cancer awarded by Bladder Cancer Advocacy Network, Inc. Key Personnel 2022 - 2023

Optimization Of Urinary DNA Deep Sequencing Tests To Enhance Clinical Staging Of Bladder Cancer Patients awarded by National Cancer Institute Principal Investigator Subaward 2021 - 2026

more ...

less ...

Background

education and training

M.B.,B.Ch., College of Medicine Assiut (Egypt) 2004

Contact

full name

Bishoy Morris Faltas

primary email

bmf9003@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Bishoy Morris Faltas Assistant Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage